WO2006048890A1 - Imatinib mesylate crystal form and process for preparation thereof - Google Patents

Imatinib mesylate crystal form and process for preparation thereof Download PDF

Info

Publication number
WO2006048890A1
WO2006048890A1 PCT/IN2005/000340 IN2005000340W WO2006048890A1 WO 2006048890 A1 WO2006048890 A1 WO 2006048890A1 IN 2005000340 W IN2005000340 W IN 2005000340W WO 2006048890 A1 WO2006048890 A1 WO 2006048890A1
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib mesylate
crystalline form
crystalline
present
solution
Prior art date
Application number
PCT/IN2005/000340
Other languages
French (fr)
Inventor
Hetalkumar Virendrabhai Patel
Raja Jyotir Jani
Rajamannar Thennati
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of WO2006048890A1 publication Critical patent/WO2006048890A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention provides imatinib mesylate in a crystalline form and a process for preparation thereof.
  • the present invention provides a non-needle shaped a- crystalline form of imatinib mesylate.
  • the present invention provides crystalline form of imatinib mesylate characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
  • the present invention also provides a process for the preparation of a crystalline form of imatinib mesylate.
  • the present invention provides a novel process for the preparation of a non-needle shaped ⁇ -crystalline form of imatinib mesylate, a methane sulfonic acid addition salt of 4-[(4-methyl-l-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl] amino] -phenyl]benzamide of formula 1.
  • the mesylate salt of Imatinib (Gleevec®) has been approved for the treatment of Chronic Myeloid Leukemia.
  • United States Patent No. 5521184 discloses N-phenyl-2-pyrimidine amine compounds including the compound of formula 1.
  • United States Patent No. 6894051 discloses that the methanesulfonic acid addition salt of imatinib (imatinib mesylate) can exist in needle- shaped ⁇ -crystalline form or non-needle-shaped ⁇ -crystalline form. It is reported that the ⁇ -crystalline form of imatinib mesylate is characterized by needle-shaped crystals, is hygroscopic and not particularly well suited to pharmaceutical formulation as solid dosage forms because of its physical properties, for example its flow characteristics are unfavourable.
  • the patent application discloses a method for preparation of the a- crystalline form of imatinib mesylate wherein a hot solution of imatinib mesylate in aqueous ethanol is cooled.
  • this process for preparation of the ⁇ -crystalline form is inconsistent, non-reproducible.
  • the patent application discloses the /3-crystalline form of imatinib mesylate and the process for its preparation.
  • particle size distribution means the distribution of equivalent spherical diameters.
  • X N denotes the particle size in microns ( ⁇ m) below which there are N% of particles.
  • Figure 2 provides infrared spectrum (IR) of the ⁇ -crystalline form of imatinib mesylate prepared according to the process of the present invention.
  • Figure 3 provides a differential scanning thermogram (DSC) of the ce-crystalline form of imatinib mesylate prepared according to the process of the present invention.
  • Figure 4 provides an optical photograph of the ⁇ -crystalline form of imatinib mesylate prepared according to the process of the present invention.
  • Figure 5 provides an optical photograph of the /3-crystalline form of imatinib mesylate.
  • the present invention provides crystalline imatinib mesylate in a non-needle shaped a- crystalline form.
  • the present invention provides crystalline imatinib mesylate in a non-needle shaped ⁇ -crystalline form having an aspect ratio between the range of about 1 to about 2, more preferably between the range of about 1 to about 1.5.
  • the present invention provides a crystalline form of imatinib mesylate characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
  • the present invention provides a crystalline form of imatinib mesylate characterized in that the water uptake is not more than 1.0% w/w, preferably not more than 0.6% w/w at 80% RH over 90 hours.
  • the present invention provides a process for the preparation of the ce-crystalline form of imatinib mesylate, a methane sulfonic acid addition salt of 4-[(4-methyl-l- piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl] benzamide of formula 1,
  • Formula 1 comprising subjecting a solution of imatinib mesylate in a solvent to thin film drying.
  • the present invention provides a process for preparation of the ⁇ -crystalline form of imatinib mesylate, comprising subjecting a solution of imatinib mesylate in a polar protic solvent to agitated thin film drying.
  • the crystalline form of imatinib mesylate of the present invention is non-needle shaped and has good flow properties.
  • the aspect ratio i.e. the ratio of mean length and mean width of the crystals may be between the range of about 1 to about 3, preferably about 1 to about 2, more preferably about 1 to about 1.5.
  • An interesting property found with the crystalline imatinib mesylate of the present invention is that the difference between the tapped and untapped density is less than 0.15 gm/ml. Without ascribing to any theory the reason for this is perhaps that the particles get distributed such that the finer particles occupy the spaces between the coarser particles so that the particles become densely packed, making the material non-fluffy, and having better flow properties.
  • the crystalline form of imatinib mesylate of the present invention is having water uptake not more than 1.0% w/w, preferably not more than 0.6% w/w at 80% RH over 90 hours.
  • the present invention provides crystalline imatinib mesylate in a non-needle shaped a- crystalline form.
  • the present invention provides crystalline imatinib mesylate in a non-needle shaped ⁇ -crystalline form having an aspect ratio between the range of about 1 to about- 2.
  • the present invention provides crystalline imatinib mesylate in a non-needle shaped ⁇ -crystalline form having an aspect ratio between the range of about 1 to about 1.5.
  • present invention provides crystalline imatinib mesylate in a non-needle shaped ⁇ -crystalline form characterized in that the particle size distribution is such that the ratio of XioiXso ⁇ X ⁇ o is in the range of 1: (2 to 8):(5 to 20), wherein X 10 , X 50 and X 90 represent the sizes below which there are 10%, 50% and 90% of the particles, respectively.
  • the present invention provides crystalline imatinib mesylate characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
  • present invention provides crystalline form of imatinib mesylate characterized in that the particle size distribution is such that the ratio of X 10 :X 50 :X9o is in the range of 1: (2 to 8):(5 to 20), wherein X 10 , X 50 and X 90 represent the sizes below which there are 10%, 50% and 90% of the particles, respectively.
  • present invention provides crystalline imatinib mesylate in a non-needle shaped ⁇ -crystalline form characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
  • the present invention also provides novel, simple and viable process for the preparation of ⁇ -crystalline form of imatinib mesylate in a consistent manner, by subjecting a solution of imatinib mesylate to thin film drying.
  • the solution of imatinib mesylate to be subjected to thin film drying for preparation of the crystalline form may be prepared in a suitable solvent.
  • the suitable solvent to prepare a solution of imatinib mesylate may be a polar protic or aprotic solvent, a non-polar solvent, water or mixture thereof.
  • a polar protic water miscible solvent may be used.
  • the polar protic solvent is an alcohol or aqueous alcohol solvent, for example, methanol, ethanol, isopropanol, n-butanol, iso-butanol, tert-butanol, water or mixture thereof. More preferably, the solvent is methanol and water.
  • the solution of imatinib mesylate to be subjected to thin film drying may be advantageously prepared using a polar protic water miscible solvent and water mixture, comprising 0 to 80% v/v, preferably 10 to 50% v/v and more preferably 15 to 30% v/v of the said polar protic solvent.
  • the concentration of imatinib mesylate in the solvent to be subjected to thin film drying may be up to 30% w/v, preferably 3 to 15% and more preferably 5 to 10% w/v.
  • the temperature at which the solution of imatinib mesylate is subjected to thin film drying may be ambient to about 90°C.
  • the flow rate may be adjusted such that from a solution of imatinib mesyalte subjected to thin film drying, the rate of drying the solvent may be 20L/hour, advantageously 10L/hour at temperature of about 60°C.
  • the time for which the process of the present invention may be carried out is variable, generally about 1 to about 12 hours depending on the factors like temperature, solvent, flow rate etc would be adequate.
  • the starting imatinib mesylate that is dissolved in a solvent to prepare a solution of imatinib mesylate may be imatinib mesylate in any form for example, a ⁇ -crystalline form, amorphous imatinib mesylate or mixture thereof. It can also be a mixture of ⁇ - crystalline form with ⁇ -crystalline form or amorphous form thereof.
  • the starting imatinib mesylate may be prepared by any method known in the literature.
  • a solution of imatinib mesylate in a suitable solvent can be subjected to agitated thin film drying (ATFD) under atmospheric pressure and/or under vacuum.
  • ATFD agitated thin film drying
  • the process of the present invention in one aspect provides crystalline imatinib mesylate in a non-needle shaped ce-crystalline form.
  • the process of the present invention provides crystalline imatinib mesylate in a non-needle shaped ⁇ -crystalline form having an aspect ratio between the range of about 1 to about 3. In one preferred embodiment the process of the present invention provides crystalline imatinib mesylate in a non-needle shaped ⁇ -crystalline form having an aspect ratio between the range of about 1 to about 2.
  • the process of the present invention provides crystalline imatinib mesylate in a non-needle shaped ⁇ -crystalline form having an aspect ratio between the range of about 1 to about 1.5.
  • the process of the present invention in another aspect provides crystalline imatinib mesylate characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
  • This crystalline form of imatinib mesylate is characterized in that the particle size distribution is such that the ratio of Xi O :X 5O :X 9 o is in the range of 1 : (2 to 8):(5 to 20), wherein X 10 , X 50 and X 90 represent the sizes below which there are 10%, 50% and 90% of the particles, respectively.
  • the crystalline form of imatinib mesylate of the present invention can be prepared conveniently by following the process of the present invention by subjecting a solution of imatinib mesylate in a solvent to thin film drying.
  • the imatinib mesylate in ⁇ -crystalline form is prepared by subjecting a solution of imatinib mesylate in methanol and water to thin film drying at vapor temperature about 50°C to about 70°C under vacuum.
  • the imatinib mesylate in ⁇ -crystalline form is prepared by subjecting a solution of imatinib mesylate in methanol and water to thin film drying at vapor temperature of about 50°C to about 70°C, optionally under vacuum, wherein methanol:water is used between the range of 1 :4 to 1 : 1 (v/v) ratio.
  • the imatinib mesylate in ⁇ -crystalline form is prepared by subjecting a solution of imatinib mesylate in methanol and water to thin film drying at vapor temperature of about 50 0 C to about 70°C, optionally under vacuum, wherein methanol and water used is 1:1 (v/v) ratio.
  • the imatinib mesylate in ⁇ -crystalline form is prepared by subjecting a solution of imatinib mesylate in methanol and water to thin film drying at vapor temperature of about 50°C to about 7O 0 C, optionally under vacuum, wherein methanol:water used is 1 :4 (v/v) ratio.
  • the crystalline form of imatinib mesylate of the present invention has good compressibility and can be used for preparing tablets by direct compression or dry granulation.
  • the tablets prepared by using the crystalline form of imatinib mesylate prepared according to process of the present invention have low friability, good surface finish and are less prone to abrasion.
  • Imatinib mesylate (2.0 Kg) is dissolved in a mixture of Methanol: water (6 Lit : 24 Lit.) at 25-30°C temperature to get a clear solution.
  • the solution was concentrated in agitated thin film drier (ATFD) with flow rate of about 18 to 20 L per hour using Peristaltic pump at vapor temperature of about 55-60 0 C under vacuum for 90 minutes.
  • the solid obtained was dried at 60-75 0 C under vacuum for 60-90 minutes.
  • the product obtained is ⁇ - crystalline form of imatinib mesylate (weight: 1.4-1.5 Kg).
  • rmatinib mesylate 500 gm is dissolved in a mixture of Methanol:water (1:1, 5.0 L) at 25-3O 0 C temperature to get a clear solution.
  • the solution was concentrated in agitated thin film drier (ATFD) with flow rate of about 10 to 12 L per hour using Peristaltic pump at vapor temperature of about 50-55 0 C under vacuum for 30 minutes.
  • the solid obtained was dried at 50-55 0 C under vacuum for 30-45 minutes.
  • the product obtained is ⁇ - crystalline form of imatinib mesylate (weight: 430.0 gm).
  • Particle size distribution data recorded by laser diffraction in a Helos Symaptec analyzer, using cyclohexane as a dispersant with sonication duration of 10.00 seconds for three batches of ⁇ -crystalline form of imatinib mesylate prepared according to process of the present invention is:
  • X 10 , X 16 , Xs 0 , X 84 , X 90 and X 99 represent the sizes below which there are 10%, 16%, 50%, 84%, 90% and 99% of the particles, respectively.
  • the table below provides the data recorded for ce-crystalline form of imatinib mesylate of the present invention compared to the known ⁇ -crystalline form of imatinib mesylate at 80% relative humidity (RH) over 90 hours.
  • Aspect Ratio Aspect ratio data recorded on Nikon microscope using 250 counts for three batches of ce- crystalline form of imatinib mesylate prepared according to process of the present invention is:
  • the Stage A ingredients are sifted through # 60 mesh s.s. screen and granulated using isopropyl alcohol, milled and the wet mass is passed through 10mm s.s. screen in comminuting mill.
  • the granules are dried in fluidized bed drier at 60°C inlet temperature till loss on drying in Halogen Moisture balance at 105°C constant weight is l-2%w/w.
  • the dried granules are milled through 1.5mm s.s. screen in comminuting mill and transferred to a blender.
  • the Stage C ingredients are sifted through # 60 mesh s.s. screen and transferred to the blender.
  • the granules are lubricated in the blender for 10 minutes.
  • the tablets are compressed at tablet weight of 290mg using 9.5mm, circular, DR punches and film coated with Stage D ingredients in a suitable coating machine.

Abstract

The present invention provides crystalline imatinib mesylate in a non-needle shaped a-crystalline form. In one aspect the present invention provides crystalline form of imatinib mesylate, characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml. The present invention also provides a novel, simple viable process for preparation of crystalline imatinib mesylate of the present invention.

Description

IMATINIB MESYLATE CRYSTAL FORM AND PROCESS FOR PREPARATION THEREOF
The present invention provides imatinib mesylate in a crystalline form and a process for preparation thereof. In one aspect the present invention provides a non-needle shaped a- crystalline form of imatinib mesylate. In another aspect the present invention provides crystalline form of imatinib mesylate characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
The present invention also provides a process for the preparation of a crystalline form of imatinib mesylate. Particularly, the present invention provides a novel process for the preparation of a non-needle shaped α-crystalline form of imatinib mesylate, a methane sulfonic acid addition salt of 4-[(4-methyl-l-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl] amino] -phenyl]benzamide of formula 1. The mesylate salt of Imatinib (Gleevec®) has been approved for the treatment of Chronic Myeloid Leukemia.
Figure imgf000003_0001
Formula 1
BACKGROUND OF THE INVENTION
United States Patent No. 5521184 discloses N-phenyl-2-pyrimidine amine compounds including the compound of formula 1.
United States Patent No. 6894051 (equivalent of WO 99/03854) discloses that the methanesulfonic acid addition salt of imatinib (imatinib mesylate) can exist in needle- shaped α-crystalline form or non-needle-shaped β-crystalline form. It is reported that the α-crystalline form of imatinib mesylate is characterized by needle-shaped crystals, is hygroscopic and not particularly well suited to pharmaceutical formulation as solid dosage forms because of its physical properties, for example its flow characteristics are unfavourable. The patent application discloses a method for preparation of the a- crystalline form of imatinib mesylate wherein a hot solution of imatinib mesylate in aqueous ethanol is cooled. However, we have found that this process for preparation of the α-crystalline form is inconsistent, non-reproducible. In order to overcome the drawbacks of the α-crystalline form, the patent application discloses the /3-crystalline form of imatinib mesylate and the process for its preparation.
We have found surprising results when we prepared crystalline imatinib mesylate by the process of thin film drying. We found that the process resulted in a crystalline imatinib mesylate in a non-needle shaped form. The process resulted in a crystalline form that has a bulk density, which is relatively insensitive to tapping and which is non-hygroscopic. This crystalline imatinib mesylate is easy to handle and convenient to process into a dosage forms, for example it can be conveniently formulated and processed into tablets by dry granulation and direct compression methods.
We have also found a process for preparation of imatinib mesyalte in α-crystalline form in a reproducible manner, which is convenient for industrial use to provide α-crystalline form of imatinib mesylate reproducibly.
Definitions:
As used herein, "particle size distribution" means the distribution of equivalent spherical diameters.
The term XN as used herein denotes the particle size in microns (μm) below which there are N% of particles.
As used herein "aspect ratio" is the ratio between the mean length and the mean width of the crystals. Figure 1 provides X-ray diffractogram of the α-crystalline form of imatinib mesylate prepared according to the process of the present invention.
Figure 2 provides infrared spectrum (IR) of the α-crystalline form of imatinib mesylate prepared according to the process of the present invention.
Figure 3 provides a differential scanning thermogram (DSC) of the ce-crystalline form of imatinib mesylate prepared according to the process of the present invention.
Figure 4 provides an optical photograph of the α-crystalline form of imatinib mesylate prepared according to the process of the present invention.
Figure 5 provides an optical photograph of the /3-crystalline form of imatinib mesylate.
SUMMARY OF THE INVENTION
The present invention provides crystalline imatinib mesylate in a non-needle shaped a- crystalline form.
m a preferred embodiment the present invention provides crystalline imatinib mesylate in a non-needle shaped α-crystalline form having an aspect ratio between the range of about 1 to about 2, more preferably between the range of about 1 to about 1.5.
In another aspect the present invention provides a crystalline form of imatinib mesylate characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
In another aspect the present invention provides a crystalline form of imatinib mesylate characterized in that the water uptake is not more than 1.0% w/w, preferably not more than 0.6% w/w at 80% RH over 90 hours. The present invention provides a process for the preparation of the ce-crystalline form of imatinib mesylate, a methane sulfonic acid addition salt of 4-[(4-methyl-l- piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl] benzamide of formula 1,
Figure imgf000006_0001
Formula 1 comprising subjecting a solution of imatinib mesylate in a solvent to thin film drying.
In preferred embodiment, the present invention provides a process for preparation of the α-crystalline form of imatinib mesylate, comprising subjecting a solution of imatinib mesylate in a polar protic solvent to agitated thin film drying.
DETAILED DESCRIPTION OF THE INVENTION
The crystalline form of imatinib mesylate of the present invention is non-needle shaped and has good flow properties. Generally, the aspect ratio i.e. the ratio of mean length and mean width of the crystals may be between the range of about 1 to about 3, preferably about 1 to about 2, more preferably about 1 to about 1.5. An interesting property found with the crystalline imatinib mesylate of the present invention is that the difference between the tapped and untapped density is less than 0.15 gm/ml. Without ascribing to any theory the reason for this is perhaps that the particles get distributed such that the finer particles occupy the spaces between the coarser particles so that the particles become densely packed, making the material non-fluffy, and having better flow properties. This results in the imatinib mesylate bulk that has good compressibility and hence convenient to process into a dosage form. Also the crystalline form of imatinib mesylate of the present invention is having water uptake not more than 1.0% w/w, preferably not more than 0.6% w/w at 80% RH over 90 hours.
The present invention provides crystalline imatinib mesylate in a non-needle shaped a- crystalline form.
In one preferred embodiment the present invention provides crystalline imatinib mesylate in a non-needle shaped α-crystalline form having an aspect ratio between the range of about 1 to about- 2.
In another preferred embodiment the present invention provides crystalline imatinib mesylate in a non-needle shaped α-crystalline form having an aspect ratio between the range of about 1 to about 1.5.
In another preferred embodiment present invention provides crystalline imatinib mesylate in a non-needle shaped α-crystalline form characterized in that the particle size distribution is such that the ratio of XioiXso÷Xθo is in the range of 1: (2 to 8):(5 to 20), wherein X10, X50 and X90 represent the sizes below which there are 10%, 50% and 90% of the particles, respectively.
In another aspect the present invention provides crystalline imatinib mesylate characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
In one preferred embodiment present invention provides crystalline form of imatinib mesylate characterized in that the particle size distribution is such that the ratio of X10:X50:X9o is in the range of 1: (2 to 8):(5 to 20), wherein X10, X50 and X90 represent the sizes below which there are 10%, 50% and 90% of the particles, respectively. In another preferred embodiment present invention provides crystalline imatinib mesylate in a non-needle shaped α-crystalline form characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
The present invention also provides novel, simple and viable process for the preparation of α-crystalline form of imatinib mesylate in a consistent manner, by subjecting a solution of imatinib mesylate to thin film drying.
The solution of imatinib mesylate to be subjected to thin film drying for preparation of the crystalline form may be prepared in a suitable solvent. The suitable solvent to prepare a solution of imatinib mesylate may be a polar protic or aprotic solvent, a non-polar solvent, water or mixture thereof.
A person of skill in the art is familiar with the terms polar protic or aprotic or a non-polar solvent. A reference is made to Chapter 3, Classification of solvents, "Solvents and Solvent effects in Organic Chemistry" second edition, Christian Reichardt, © VCH, 1988.
Preferably a polar protic water miscible solvent may be used. For example, the polar protic solvent is an alcohol or aqueous alcohol solvent, for example, methanol, ethanol, isopropanol, n-butanol, iso-butanol, tert-butanol, water or mixture thereof. More preferably, the solvent is methanol and water.
The solution of imatinib mesylate to be subjected to thin film drying may be advantageously prepared using a polar protic water miscible solvent and water mixture, comprising 0 to 80% v/v, preferably 10 to 50% v/v and more preferably 15 to 30% v/v of the said polar protic solvent.
The concentration of imatinib mesylate in the solvent to be subjected to thin film drying may be up to 30% w/v, preferably 3 to 15% and more preferably 5 to 10% w/v. The temperature at which the solution of imatinib mesylate is subjected to thin film drying may be ambient to about 90°C.
The flow rate may be adjusted such that from a solution of imatinib mesyalte subjected to thin film drying, the rate of drying the solvent may be 20L/hour, advantageously 10L/hour at temperature of about 60°C.
The time for which the process of the present invention may be carried out is variable, generally about 1 to about 12 hours depending on the factors like temperature, solvent, flow rate etc would be adequate. For a batch of about 2 Kg quantity in a solvent like methanol and water, generally about 2 to about 3 hours would be sufficient at vapour temperature of about 600C with flow rate of about 10 to about 20L/hour.
The starting imatinib mesylate that is dissolved in a solvent to prepare a solution of imatinib mesylate may be imatinib mesylate in any form for example, a β-crystalline form, amorphous imatinib mesylate or mixture thereof. It can also be a mixture of α- crystalline form with β-crystalline form or amorphous form thereof. The starting imatinib mesylate may be prepared by any method known in the literature.
hi the process of the present invention to prepare ocrystalline form of imatininb mesylate, a solution of imatinib mesylate in a suitable solvent can be subjected to agitated thin film drying (ATFD) under atmospheric pressure and/or under vacuum.
The process of the present invention in one aspect provides crystalline imatinib mesylate in a non-needle shaped ce-crystalline form.
hi a preferred embodiment the process of the present invention provides crystalline imatinib mesylate in a non-needle shaped α-crystalline form having an aspect ratio between the range of about 1 to about 3. In one preferred embodiment the process of the present invention provides crystalline imatinib mesylate in a non-needle shaped α-crystalline form having an aspect ratio between the range of about 1 to about 2.
In another preferred embodiment the process of the present invention provides crystalline imatinib mesylate in a non-needle shaped α-crystalline form having an aspect ratio between the range of about 1 to about 1.5.
The process of the present invention in another aspect provides crystalline imatinib mesylate characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
This crystalline form of imatinib mesylate is characterized in that the particle size distribution is such that the ratio of XiO:X5O:X9o is in the range of 1 : (2 to 8):(5 to 20), wherein X10, X50 and X90 represent the sizes below which there are 10%, 50% and 90% of the particles, respectively.
The crystalline form of imatinib mesylate of the present invention can be prepared conveniently by following the process of the present invention by subjecting a solution of imatinib mesylate in a solvent to thin film drying.
In a preferred embodiment the imatinib mesylate in α-crystalline form is prepared by subjecting a solution of imatinib mesylate in methanol and water to thin film drying at vapor temperature about 50°C to about 70°C under vacuum.
In another preferred embodiment the imatinib mesylate in α-crystalline form is prepared by subjecting a solution of imatinib mesylate in methanol and water to thin film drying at vapor temperature of about 50°C to about 70°C, optionally under vacuum, wherein methanol:water is used between the range of 1 :4 to 1 : 1 (v/v) ratio. In another preferred embodiment the imatinib mesylate in α-crystalline form is prepared by subjecting a solution of imatinib mesylate in methanol and water to thin film drying at vapor temperature of about 500C to about 70°C, optionally under vacuum, wherein methanol and water used is 1:1 (v/v) ratio.
In another preferred embodiment the imatinib mesylate in α-crystalline form is prepared by subjecting a solution of imatinib mesylate in methanol and water to thin film drying at vapor temperature of about 50°C to about 7O0C, optionally under vacuum, wherein methanol:water used is 1 :4 (v/v) ratio.
The crystalline form of imatinib mesylate of the present invention has good compressibility and can be used for preparing tablets by direct compression or dry granulation. The tablets prepared by using the crystalline form of imatinib mesylate prepared according to process of the present invention have low friability, good surface finish and are less prone to abrasion.
The examples that follow do not limit the scope of the present invention and are merely used as illustrations.
EXAMPLES
Example 1
Preparation of α-form of imatinib mesylate:
Imatinib mesylate (2.0 Kg) is dissolved in a mixture of Methanol: water (6 Lit : 24 Lit.) at 25-30°C temperature to get a clear solution. The solution was concentrated in agitated thin film drier (ATFD) with flow rate of about 18 to 20 L per hour using Peristaltic pump at vapor temperature of about 55-600C under vacuum for 90 minutes. The solid obtained was dried at 60-750C under vacuum for 60-90 minutes. The product obtained is α- crystalline form of imatinib mesylate (weight: 1.4-1.5 Kg).
Example 2
Preparation of α-form of imatinib mesylate: rmatinib mesylate (500 gm) is dissolved in a mixture of Methanol:water (1:1, 5.0 L) at 25-3O0C temperature to get a clear solution. The solution was concentrated in agitated thin film drier (ATFD) with flow rate of about 10 to 12 L per hour using Peristaltic pump at vapor temperature of about 50-550C under vacuum for 30 minutes. The solid obtained was dried at 50-550C under vacuum for 30-45 minutes. The product obtained is α- crystalline form of imatinib mesylate (weight: 430.0 gm).
Given below is the data recorded for three batches of α-crystalline form of imatinib mesylate prepared according to process of the present invention.
Density:
Figure imgf000012_0001
In contrast, it was found that the difference in tapped and untapped densities of the /S- crystalline form of imatinib mesylate was in the range of 0.17 to 0.26. Particle size distribution data:
Particle size distribution data recorded by laser diffraction in a Helos Symaptec analyzer, using cyclohexane as a dispersant with sonication duration of 10.00 seconds for three batches of α-crystalline form of imatinib mesylate prepared according to process of the present invention is:
Figure imgf000013_0001
wherein X10, X16, Xs0, X84, X90 and X99 represent the sizes below which there are 10%, 16%, 50%, 84%, 90% and 99% of the particles, respectively.
The table below provides the data recorded for ce-crystalline form of imatinib mesylate of the present invention compared to the known β-crystalline form of imatinib mesylate at 80% relative humidity (RH) over 90 hours.
Figure imgf000013_0002
It is apparent that the α-crystalline form of imatinib mesylate prepared by the process of the invention is stable and the % weigh gain in moisture is not more than 0.6% at 80%RH over 90 hours.
Aspect Ratio: Aspect ratio data recorded on Nikon microscope using 250 counts for three batches of ce- crystalline form of imatinib mesylate prepared according to process of the present invention is:
Figure imgf000014_0001
Example 3:
Tablets of imatinib mesylate (100 mg) prepared according to thin film drying process
Figure imgf000014_0002
The Stage A ingredients are sifted through # 60 mesh s.s. screen and granulated using isopropyl alcohol, milled and the wet mass is passed through 10mm s.s. screen in comminuting mill. The granules are dried in fluidized bed drier at 60°C inlet temperature till loss on drying in Halogen Moisture balance at 105°C constant weight is l-2%w/w. The dried granules are milled through 1.5mm s.s. screen in comminuting mill and transferred to a blender. The Stage C ingredients are sifted through # 60 mesh s.s. screen and transferred to the blender. The granules are lubricated in the blender for 10 minutes. The tablets are compressed at tablet weight of 290mg using 9.5mm, circular, DR punches and film coated with Stage D ingredients in a suitable coating machine.

Claims

We Claim
1. Crystalline imatinib mesylate in a non-needle shaped α-crystalline form.
2. Crystalline imatinib mesylate in a non-needle shaped α-crystalline form having an aspect ratio between the range of about 1 to about 2.
3. Crystalline imatinib mesylate in a non-needle shaped α-crystalline form having an aspect ratio between the range of about 1 to about 1.5.
4. The crystalline form of imatinib mesylate as claimed in claim 1, characterized in that the particle size distribution is such that the ratio of Xio:X5O:X9o is in the range of 1 : (2 to 8):(5 to 20), wherein Xjo, X50 and X90 represent the sizes below which there are 10%, 50% and 90% of the particles, respectively.
5. Crystalline form of imatinib mesylate, characterized in that the difference between the tapped and untapped density is less than 0.15 gm/ml.
6. The crystalline form of imatinib mesylate as claimed in claim 5, characterized in that the particle size distribution is such that the ratio of Xlo:X5o:X9O is in the range of 1:
(2 to 8):(5 to 20), wherein X10, X50 and X90 represent the sizes below which there are 10%, 50% and 90% of the particles, respectively.
7. Crystalline form of imatinib mesylate prepared by a process comprising subjecting a solution of imatinib mesylate in a solvent to thin film drying.
8. A process for the preparation of the α-crystalline form of imatinib mesylate, comprising subjecting a solution of imatinib mesylate in a solvent to thin film drying.
9. The process as claimed in claim 8, wherein the solution of imatinib mesylate is in a polar protic solvent.
10. The process as claimed in claim 9, wherein the solvent is an alcohol or aqueous alcohol solvent selected from a group consisting of methanol, ethanol, isopropanol, n- butanol, iso-butanol, tert-butanol and water or mixture thereof.
11. The process as claimed in claim 10, wherein the solution of imatinib mesylate is in methanol and water.
12. The process as claimed in claim 11, wherein the solution of imatinib mesylate is subjected to thin film drying at temperature of about 50°C to about 7O0C under vacuum.
13. Crystalline form of imatinib mesylate prepared according to the process of claim 12.
PCT/IN2005/000340 2004-11-04 2005-10-20 Imatinib mesylate crystal form and process for preparation thereof WO2006048890A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1188/MUM/2004 2004-11-04
IN1188MU2004 2004-11-04

Publications (1)

Publication Number Publication Date
WO2006048890A1 true WO2006048890A1 (en) 2006-05-11

Family

ID=36318937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000340 WO2006048890A1 (en) 2004-11-04 2005-10-20 Imatinib mesylate crystal form and process for preparation thereof

Country Status (1)

Country Link
WO (1) WO2006048890A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121941A2 (en) * 2005-05-10 2006-11-16 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2007023182A1 (en) * 2005-08-26 2007-03-01 Novartis Ag Delta and epsilon crystal forms of imatinib mesylate
WO2007059963A1 (en) * 2005-11-25 2007-05-31 Novartis Ag F,g,h,i and k crystal forms of imatinib mesylate
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
WO2010133976A2 (en) 2009-05-22 2010-11-25 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
JP2010540465A (en) * 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド Stable imatinib composition
WO2011023146A1 (en) 2009-08-26 2011-03-03 Zentiva, K.S. Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions
EP2311821A1 (en) 2006-04-27 2011-04-20 Sicor, Inc. Polymorphic form of Imatinib mesylate and processes for its preparation
WO2011049474A1 (en) 2009-10-22 2011-04-28 Tomasz Kozluk Salts of imatinib with tartaric acids
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
CN102146073A (en) * 2011-02-23 2011-08-10 江苏先声药物研究有限公司 New preparation method of alpha crystal form of imatinib mesylate
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011099039A1 (en) 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
WO2011108953A1 (en) 2010-03-04 2011-09-09 Tomasz Kozluk PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
CN102552268A (en) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 Medicinal preparation containing crystal form a imatinib mesylate
CN102617552A (en) * 2012-04-06 2012-08-01 江南大学 Crystallizing method for preparing alpha crystal form methanesulfonic acid imatinib
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
WO2013136141A1 (en) 2012-03-13 2013-09-19 Fresenius Kabi Oncology Ltd. An improved process for the preparation of alpha form of imatinib mesylate
CN103476770A (en) * 2010-11-25 2013-12-25 拉蒂欧制药有限责任公司 Novel salts and polymorphic forms of afatinib
EP2749557A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
US8912325B2 (en) 2011-03-31 2014-12-16 Ind-Swift Laboratories Limited Process for preparation of imatinib and its mesylate salt
CN104478854A (en) * 2014-11-13 2015-04-01 江苏豪森药业股份有限公司 Preparation method of imatinib mesylate of non-acicular crystal form
CN104761539A (en) * 2015-04-14 2015-07-08 江苏豪森药业股份有限公司 Method for directionally preparing mesylate imatinib non-acicular alpha crystal form in high efficiency
CN104817536A (en) * 2015-04-14 2015-08-05 江苏豪森药业股份有限公司 Medicinal imatinib mesylate non-acicular alpha crystal form and preparation method thereof
WO2015188243A1 (en) * 2014-06-10 2015-12-17 Cristália Produtos Químicos Farmacêuticos Ltda PROCESS FOR PREPARING IMATINIB AND IMATINIB MESYLATE NON-NEEDLE SHAPED α2 FORM
CN105399724A (en) * 2015-11-05 2016-03-16 齐鲁天和惠世制药有限公司 Preparation method of non-acicular alpha crystal form imatinib mesylate
EP3007699A4 (en) * 2013-06-12 2017-01-18 Shilpa Medicare Limited Crystalline imatinib mesylate process
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2005077933A1 (en) * 2004-02-11 2005-08-25 Natco Pharma Limited Novel polymorphic form of imatinib mesylate and a process for its preparation
WO2005095379A2 (en) * 2004-04-02 2005-10-13 Instytut Farmaceutyczny Crystalline methanesulfonic acid addition salts of imatinib
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2005077933A1 (en) * 2004-02-11 2005-08-25 Natco Pharma Limited Novel polymorphic form of imatinib mesylate and a process for its preparation
WO2005095379A2 (en) * 2004-04-02 2005-10-13 Instytut Farmaceutyczny Crystalline methanesulfonic acid addition salts of imatinib
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2006121941A3 (en) * 2005-05-10 2007-01-11 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
WO2006121941A2 (en) * 2005-05-10 2006-11-16 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US7879860B2 (en) 2005-08-26 2011-02-01 Novartis Ag Delta and epsilon crystal forms of Imatinib mesylate
WO2007023182A1 (en) * 2005-08-26 2007-03-01 Novartis Ag Delta and epsilon crystal forms of imatinib mesylate
US8633213B2 (en) 2005-11-25 2014-01-21 Novartis Ag Crystalline form F of imatinib mesylate
US8846706B2 (en) 2005-11-25 2014-09-30 Novartis Ag Crystalline form K of imatinib mesylate
EP2546248A1 (en) * 2005-11-25 2013-01-16 Novartis AG Crystal form H of imatinib mesylate
EP2578580A1 (en) * 2005-11-25 2013-04-10 Novartis AG G, I and K crystal forms of imatinib mesylate
US7893076B2 (en) 2005-11-25 2011-02-22 Novartis Ag Crystalline form F of Imatinib mesylate
US8198289B2 (en) 2005-11-25 2012-06-12 Novartis Ag Crystal form H imatinib mesylate for pharmaceutical use
US8507515B2 (en) 2005-11-25 2013-08-13 Novartis Ag Crystalline form G of imatinib mesylate
US8592440B2 (en) 2005-11-25 2013-11-26 Novartis Ag Crystalline form I of imatinib mesylate
WO2007059963A1 (en) * 2005-11-25 2007-05-31 Novartis Ag F,g,h,i and k crystal forms of imatinib mesylate
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP2829538A1 (en) 2006-04-27 2015-01-28 Sicor, Inc. Polymorphic form of imatinib mesylate and process for its preparation
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
EP2311821A1 (en) 2006-04-27 2011-04-20 Sicor, Inc. Polymorphic form of Imatinib mesylate and processes for its preparation
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
JP2010540465A (en) * 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド Stable imatinib composition
US7947699B2 (en) 2008-01-10 2011-05-24 Actavis Group Ptc Ehf Anhydrous amorphous imatinib mesylate
WO2010133976A2 (en) 2009-05-22 2010-11-25 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
WO2011023146A1 (en) 2009-08-26 2011-03-03 Zentiva, K.S. Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions
WO2011049474A1 (en) 2009-10-22 2011-04-28 Tomasz Kozluk Salts of imatinib with tartaric acids
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011099039A1 (en) 2010-02-15 2011-08-18 Reliance Life Sciences Pvt. Ltd. Process for the preparation of alpha form of imatinib mesylate
WO2011108953A1 (en) 2010-03-04 2011-09-09 Tomasz Kozluk PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
CN103476770B (en) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 Salts and polymorphic forms of afatinib
CN103476770A (en) * 2010-11-25 2013-12-25 拉蒂欧制药有限责任公司 Novel salts and polymorphic forms of afatinib
CN102552268A (en) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 Medicinal preparation containing crystal form a imatinib mesylate
CN102146073A (en) * 2011-02-23 2011-08-10 江苏先声药物研究有限公司 New preparation method of alpha crystal form of imatinib mesylate
US8912325B2 (en) 2011-03-31 2014-12-16 Ind-Swift Laboratories Limited Process for preparation of imatinib and its mesylate salt
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
WO2013136141A1 (en) 2012-03-13 2013-09-19 Fresenius Kabi Oncology Ltd. An improved process for the preparation of alpha form of imatinib mesylate
CN102617552A (en) * 2012-04-06 2012-08-01 江南大学 Crystallizing method for preparing alpha crystal form methanesulfonic acid imatinib
EP2749557A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
EP3007699A4 (en) * 2013-06-12 2017-01-18 Shilpa Medicare Limited Crystalline imatinib mesylate process
WO2015188243A1 (en) * 2014-06-10 2015-12-17 Cristália Produtos Químicos Farmacêuticos Ltda PROCESS FOR PREPARING IMATINIB AND IMATINIB MESYLATE NON-NEEDLE SHAPED α2 FORM
CN104478854A (en) * 2014-11-13 2015-04-01 江苏豪森药业股份有限公司 Preparation method of imatinib mesylate of non-acicular crystal form
CN104761539A (en) * 2015-04-14 2015-07-08 江苏豪森药业股份有限公司 Method for directionally preparing mesylate imatinib non-acicular alpha crystal form in high efficiency
CN104817536A (en) * 2015-04-14 2015-08-05 江苏豪森药业股份有限公司 Medicinal imatinib mesylate non-acicular alpha crystal form and preparation method thereof
CN106518844A (en) * 2015-04-14 2017-03-22 江苏豪森药业集团有限公司 An imatinib mesylate crystal form suitable for officinal uses and a preparing method thereof
CN105399724A (en) * 2015-11-05 2016-03-16 齐鲁天和惠世制药有限公司 Preparation method of non-acicular alpha crystal form imatinib mesylate
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib

Similar Documents

Publication Publication Date Title
WO2006048890A1 (en) Imatinib mesylate crystal form and process for preparation thereof
JP4104687B2 (en) Novel crystal modification of CDCH, process for its production and pharmaceutical preparation containing this modification
US8884013B2 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
RU2526038C2 (en) Tosylate salt of 5-pyrazolyl-2-pyridone derivative effective in copd treatment
WO2009114601A2 (en) Preparation of lenalidomide
JP2010523589A (en) Solid form of pemetrexed
US9376419B2 (en) Solid forms of nilotinib hydrochloride
EP2291366A2 (en) Preparation of imatinib mesylate
EP3219710B1 (en) Crystal form of potassium-competitive acid blockers and preparation method therefor
DK2838892T3 (en) ISOLATED SOLID FORM OF LOW CHLORIDE ANAMORELINE MONOHYDROCHLORIDE: ANAMOLERINE MOLF RATIO AND LOW CONTENT OF ORGANIC SOLVENT
Veverka et al. Imatinib mesylate cocrystals: synthesis, screening, and preliminary characterization
WO2017190715A1 (en) An amorphous form of sofosbuvir, a method of its preparation and its stabilization
JP2009511627A (en) Polymorphic transition of zolpidem in tablet matrix
US10752618B2 (en) Process for the preparation of pure and stable crystalline Raltegravir potassium form 3
WO2020225827A1 (en) Novel polymorphs of ribociclib succinate
EP2924024A2 (en) Solid forms of lorcaserin hydrochloride
US9670184B2 (en) Amorphous allisartan isoproxil, preparation method therefor, and pharmaceutical composition containing amorphous allisartan isoproxil
CN109796400B (en) Sorafenib tosylate crystal form and preparation method thereof
WO2011085130A1 (en) Solid state forms of fosamprenavir calcium salt and process for preparation thereof
US20230105181A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
WO2011095984A1 (en) A process for the preparation of amorphous esomeprazole
EP3707124A1 (en) Amorphous form of pimavanserin hemitartrate
CA3094588A1 (en) Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05823677

Country of ref document: EP

Kind code of ref document: A1